MAR 10, 2020 8:13 PM PDT

Chemo more effective with Intralipid treatment

A study published recently in Scientific Reports suggests a novel technique to make chemotherapy more effective. The technique couples chemotherapy nanodrugs with a nutritional supplement called Intralipid to decrease side effects during treatment and cut the quantify of drugs needed for treatment. Coming from Carnegie Mellon University and Taiwan's National Health Research Institutes, the technique was originally developed by Emeritus Professor of Biological Sciences Chien Ho in 2015 and has since advanced in its progress. It will begin early-stage clinical trials in the near future.

One of the complications of chemotherapy stems from the difficulties of drug delivery. Although certain nanodrugs are indeed quite good at destroying cancer cells, in many cases, very small quantities of the drugs actually reach cancer tumor cells. That’s certainly the case with paclitaxel, a nanodrug that is used in chemotherapy. Estimates report that less than 1% of the drug reaches tumors, while the rest of it gets taken up by healthy cells in the individual’s organs, resulting in toxic side-effects.

In this study, the researchers looked at a specific kind of paclitaxel called Abraxane. They wanted to see how pairing Intralipid nutrient supplements with Abraxane would affect cells. "The combination of anti-cancer nanodrugs with Intralipid enhances the inhibition of tumor growth and may serve as a novel strategy to improve therapeutic efficacy in treating cancers in clinical practice," observed Ho.  

Additionally, the researchers figured out that administering the supplement prior to chemotherapy also prevented damage to monocytic white blood cells. In tests with pancreatic, breast, and lung cancer cells in mice models, they found that the presence of Intralipid with the Abraxane acted to convert macrophages into the M1 phenotype, thereby encouraging the generation of macrophages that kill tumor cells.

Ultimately, the goal of this research is to reduce the side effects brought on by chemotherapy and cut the amounts of drugs that are necessary during treatment while maintaining effectiveness. These end goals have very real implications both financially and for patients’ health and well-being. That’s why the last conclusion from this study is so encouraging: the researchers showed that it is possible to pretreat with Intralipid and then give only half the standard dosage of Abraxane without losing any effectiveness.

"By decreasing the amount of Abraxane needed in treating cancers, we can protect the organs from some of the chemical damage done by the drug," elaborated Ho.

The presence of Intralipid with the Abraxane converts macrophages into the M1 phenotype. Photo: Pixabay

The researchers believe their technique could hold significant implications for other nanodrug treatments. "This new nanodrug delivery method is a general one and can be applied to other approved and in-development nanodrugs without any modifications to the drugs or their carriers," said Ho. "This drug delivery method can reduce the amount of drugs needed for treatment, improving the quality of life for patients and reducing the cost of treatment with these expensive drugs."

Sources: Scientific Reports, Eureka Alert!

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
APR 06, 2021
Immunology
Lymphoma Patient Cured by "Reeducating" their Immune System
APR 06, 2021
Lymphoma Patient Cured by "Reeducating" their Immune System
Australian researchers have used a breakthrough therapy to cure a patient diagnosed with a rare brain lymphoma, a form o ...
MAY 11, 2021
Immunology
Immune Cells Help Brain Tumors Spread, but We Can Stop Them
MAY 11, 2021
Immune Cells Help Brain Tumors Spread, but We Can Stop Them
Researchers have discovered how a glitch in the brain’s immune system can inadvertently cause an accelerated growt ...
MAY 13, 2021
Cancer
Ovarian cancer screening doesn't save lives, reports new study
MAY 13, 2021
Ovarian cancer screening doesn't save lives, reports new study
New research published in the journal The Lancet highlights the eagerly awaited results of the UK Collaborative Trial of ...
MAY 16, 2021
Cancer
Can you guess which drug is both antiviral and immunotherapeutic?
MAY 16, 2021
Can you guess which drug is both antiviral and immunotherapeutic?
Hepatitis B virus (HBV) is the most common cause of liver cancer in the world, resulting in approximately 880,000 deaths ...
JUN 05, 2021
Cancer
How is the new hospital price transparency rule going?
JUN 05, 2021
How is the new hospital price transparency rule going?
New findings from an analysis of hospital price transparency have been published recently in JAMA. The analysis was ...
JUN 04, 2021
Cancer
Cancer patients with COVID-19 fare better with remote health monitoring
JUN 04, 2021
Cancer patients with COVID-19 fare better with remote health monitoring
A new study presented last week at the American Society of Clinical Oncology Annual Meeting after its publication in the ...
Loading Comments...